Circulating exosomal lncRNAs in patients with chronic coronary syndromes

Abstract

IntroductionThe concept of chronic coronary syndrome (CCS) was first presented at the European Society of Cardiology Meeting in 2019. However, the roles of exosomal lncRNAs in CCS remain largely unclear.Material and methodsA case-control study was performed with a total of 218 participants (137 males and 81 females), including 15 CCS patients and 15 controls for sequencing profiles, 20 CCS patients and 20 controls for the first validation, and 100 CCS patients and 48 controls for the second validation. Exosomes were isolated from the plasma of CCS patients and controls, and exosomal lncRNAs were identified by sequencing profiles and verified twice by qRT-PCR analysis. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of exosomal lncRNAs for CCS patients.ResultsA total of 152 significantly differentially expressed lncRNAs with over two-fold changes were detected in plasma exosomes of CCS patients, including 90 upregulated and 62 downregulated lncRNAs. Importantly, 6 upregulated lncRNAs with the top fold changes were selected for validations. Exosomal lncRNAs ENST00000424615.2 and ENST00000560769.1 were significantly elevated in CCS patients in both validations compared with controls. The areas under the ROC of lncRNAs ENST00000424615.2 and ENST00000560769.1 were 0.654 and 0.722, respectively. Additionally, exosomal lncRNA ENST00000560769.1 was significantly higher in the CCS patients with more diseased vessels (p = 0.028).ConclusionsExosomal lncRNA ENST00000424615.2 and ENST00000560769.1 were identified as novel diagnosis biomarkers for patients with CCS. Moreover, exosomal lncRNA ENST00000560769.1 was significantly higher in the CCS patients with more diseased vessels, and might be associated with a poor prognosis.

Circulating Exosomal CircRNAs as Diagnostic Biomarkers for Chronic Coronary Syndrome

“…Fifteen CCS patients and 15 NCCP subjects were included for RNA sequencing. For the baseline characteristics of the sequencing samples, please see our previously published data [12]. The assessment of clinical characteristics revealed no statistical difference between CCS patients and the controls in terms of age, sex, hypertension, diabetics, family history, heart rate, systolic blood pressure, diastolic blood pressure, body mass index, or laboratory data.…”

“…One hundred and thirty-five patients diagnosed with CCS and 83 patients with noncardiogenic chest pain (NCCP) were included from our previous work [12]. The diagnosis of CCS is according to definition in the European Society of Cardiology (ESC) Clinical Practice Guidelines in 2019 [2], and patients with coronary artery stenosis ≥ 50% on angiography were included in this study [13].…”

“…A total of 218 subjects were included in the present study and all the participants were divided into three cohorts as our previous study [12]: the sequencing cohort, including 15 CCSs and 15 NCCPs (to obtain the circulating exosomal circRNAs profile and candidate circRNAs by high-throughput sequencing); the first validation cohort, including 20 CCSs and 20 controls (to validate candidate exosomal circRNAs in a small group of patients using real-time quantitative PCR (RT-qPCR)); and the second validation cohort, including 100 CCSs and 48 NCCPs (to confirm exosomal circRNAs obtained in the first validation cohort in a larger group of patients) (Figure 1). The study was conducted in accordance with the Declaration of Helsinki, and the research protocol was approved by the Ethics Committee of Beijing Chao-Yang Hospital (2016-ke-101).…”

“…To identify potential exosomal circRNAs that can be served as CCS diagnostic biomarkers, the five candidate exosomal circRNAs were detected in the first validation cohort, which includes 20 CCSs and 20 NCCPs, using RT-qPCR. For the clinical characters of the first validation cohort, please see our previously published data [12]. The analysis of clinical features showed that patients with CCS were older and had significantly increased level of leukocyte and neutrophil than the NCCP controls.…”

Harnessing the potential of long non-coding RNAs in breast cancer: from etiology to treatment resistance and clinical applications

“…Moreover, unlike traditional in-situ biopsies, exosomes can be isolated from easily accessible body fluids like blood and urine, without the need for more invasive procedures. This makes the process of monitoring exosomes in body fluids much more convenient, feasible, and less invasive for patients ( 38 ). As a result, the utilization of exosomal lncRNAs as biomarkers holds great promise in advancing cancer detection and management.…”